SecBot SecBot
8-K ·Filed Jul 13, 2026

AGEN

AGENUS INC
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001193125-26-301414
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The financing removes near-term cash runway risk and funds critical Phase 3 catalysts, but the massive dilution will pressure the stock. Watch for the pathological complete response data trigger (≥50 patients) that accelerates Series B warrant expiration, early positive data could reduce overhang. The board designation by Commodore adds activist-like oversight, potentially improving governance.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

AGEN drug pipeline →

botensilimab

◆ Mixed Named in this 8-K
Impact
Phase
Phase 3
Time to market
At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
Next catalyst
None dated

What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.12
T+0 close · Jul 13, 2026 · via day close
Latest settled
+22.39%
T+60 · $7.49
Vs SPY
+18.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $6.12entry
  2. T+1 · 4mo ago −16.99%α −17.35% · $5.08
  3. T+5 · 4mo ago −18.14%α −17.35% · $5.01
  4. T+20 · 3mo ago +14.38%α +11.19% · $7.00
  5. T+60 · 6w ago +22.39%α +18.39% · $7.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Agenus entered into a securities purchase agreement for a ~$85M PIPE financing led by Commodore Capital, issuing shares at $3.69 along with Series A ($4.02 strike) and Series B ($5.03 strike) warrants. Proceeds will fund the Phase 3 neoadjuvant trial of botensilimab/balstilimab in colon cancer and extend operating runway through key readouts. The offering is highly dilutive relative to the $140M market cap, but the cash infusion and board designation rights for Commodore provide a governance backstop.

Key Financial Metrics

Offering Size
$85.0M

Key Facts

  • ~$85M PIPE priced at $3.69 per share (with warrants), plus pre-funded warrants at $3.68
  • Series A warrants exercisable at $4.02; Series B warrants at $5.03
  • Series A warrants expire 30 days after 60 patients dosed in Phase 3 colon cancer trial; Series B warrants expire 30 days after pathologic response data for ≥50 patients
  • Lead investor Commodore Capital Master LP receives board designation rights (two directors) upon reaching 5% beneficial ownership
  • Proceeds used for general corporate purposes and to extend runway through pCR, interim EFS, and final EFS readouts for BOT/BAL in colon cancer
  • 90-day lockup on further equity issuance without lead investor consent
  • Company to use commercially reasonable efforts to extend $24.75M promissory note maturity with Ocean 1181 LLC

Financial Impact

~$85M gross proceeds; dilution of approximately 61% of pre-offering market cap from shares and pre-funded warrants, with additional potential dilution from Series A and B warrants

dilutioncash runwayshare count

Risk Factors

  • Significant dilution from the offering and warrants could weigh on share price
  • Clinical trial risk: BOT/BAL Phase 3 colon cancer data may fail to meet endpoints
  • Potential need for additional financing if trial readouts are delayed or negative
  • Warrant overhang: Series A and B warrants could be exercised, adding further dilution

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-301414
Document: d111026dex102.htm0001193125-26-301414
Document: d111026dex43.htm0001193125-26-301414
Document: d111026dex42.htm0001193125-26-301414

Track record

12 reports on AGEN

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.35 Now $6.29 −0.94% settles Feb 16
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
  4. Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
  6. Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
  7. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
  8. Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
  9. Jul 13, 202618w ago 8-K Bearish 6/10 Viewing Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
  10. May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 8h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026